Details for New Drug Application (NDA): 071614
✉ Email this page to a colleague
NDA 071614 describes DIAZEPAM, which is a drug marketed by Chartwell Molecular, Novel Labs Inc, Abraxis Pharm, Alembic, Beloteca, Dr Reddys, Fresenius Kabi Usa, Hikma, Hospira, Long Grove Pharms, Marsam Pharms Llc, Parenta Pharms, Us Army, Warner Chilcott, Watson Labs, Watson Labs Inc, Actavis Elizabeth, Aurobindo Pharma Ltd, Barr, Chartwell Rx, Dr Reddys Labs Sa, Duramed Pharms Barr, Endo Operations, Ferndale Labs, Halsey, Ivax Sub Teva Pharms, Martec Usa Llc, Mylan, Nuvo Pharm, Pioneer Pharms, Roxane, Strides Pharma, Teva Pharms, and Virtus, and is included in seventy-nine NDAs. It is available from forty-one suppliers. Additional details are available on the DIAZEPAM profile page.
The generic ingredient in DIAZEPAM is diazepam. There are eight drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the diazepam profile page.
The generic ingredient in DIAZEPAM is diazepam. There are eight drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the diazepam profile page.
Summary for 071614
| Tradename: | DIAZEPAM |
| Applicant: | Warner Chilcott |
| Ingredient: | diazepam |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 071614
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 5MG/ML | ||||
| Approval Date: | Oct 22, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
